Stockscreener 앱 받기
30.74
6.28%
-2.06
전일 마감가:
$32.80
열려 있는:
$32.8
하루 거래량:
246.92K
Relative Volume:
0.70
시가총액:
$2.34B
수익:
-
순이익/손실:
-
주가수익비율:
-
EPS:
-
순현금흐름:
-
1주 성능:
-19.51%
1개월 성능:
-48.77%
6개월 성능:
+0.00%
1년 성능:
+0.00%
1일 변동 폭
$30.62
$37.85
1주일 범위
$26.21
$40.25
52주 변동 폭
$9.95
$67.00
Jyong Biotech Ltd Stock (MENS) Company Profile
MENS을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
MENS
Jyong Biotech Ltd
|
30.74 | 2.49B | 0 | 0 | 0 | 0.00 |
|
VRTX
Vertex Pharmaceuticals Inc
|
426.76 | 107.15B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
755.90 | 77.46B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
436.38 | 58.90B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
918.92 | 56.55B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
198.76 | 42.58B | 447.02M | -1.18B | -906.14M | -6.1812 |
Jyong Biotech Ltd 주식(MENS)의 최신 뉴스
Jyong Biotech (NASDAQ:MENS) Shares Up 10.9%Should You Buy? - MarketBeat
Jyong Biotech completes primary endpoint analysis for Phase II trial of MCS-8 - Yahoo Finance
Exploring Jyong Biotech’s (NasdaqGM:MENS) Valuation Following Recent Share Price Volatility - Yahoo Finance
Jyong Biotech reports positive results for prostate cancer drug in phase II trial - Investing.com Nigeria
Jyong Biotech stock soars after positive Phase II prostate cancer drug results - Investing.com India
Jyong Biotech Says Phase 2 Trial of MCS-8 in Prostate Cancer Meets Efficacy Endpoints - MarketScreener
Jyong Biotech Announces Completion of Primary Endpoint Statistical Analysis for Phase II Clinical Trial of MCS-8 With Positive Outcomes - The Manila Times
Jyong Biotech (Nasdaq: MENS) MCS-8 Phase II Cuts Prostate Cancer 27%, High-Grade 17% - Stock Titan
Jyong Biotech (NASDAQ:MENS) Shares Gap DownTime to Sell? - MarketBeat
Jyong Biotech Ltd. (MENS) Analyst insights, Price targets and Recommendations - Yahoo Finance UK
Jyong Biotech (NASDAQ:MENS) Shares Gap UpStill a Buy? - MarketBeat
Jyong Biotech plunges 49% after InvestingPro’s overvalued warning By Investing.com - Investing.com South Africa
Google, Alibaba among market cap stock movers on Monday - Investing.com
12 Health Care Stocks Moving In Monday's Intraday Session - Benzinga
Google and Micron among market cap stock movers on Monday By Investing.com - Investing.com UK
Google and Micron among market cap stock movers on Monday - Investing.com India
Jyong Biotech (MENS US): Taiwan-Based, US-Listed, Excluded from US & Global Indices - Smartkarma
Jyong Biotech (NASDAQ:MENS) Trading Down 8%Here's Why - MarketBeat
Dow notches record-high close while tech-heavy Nasdaq slips - Yahoo Finance
Dow notches record high close, traders bet on end to shutdown - Yahoo Finance
Health insurers slide after subsidies dropped from US shutdown deal - Yahoo Finance
Global shares jump as investors eye potential end to US shutdown - Yahoo Finance
Wall Street ends higher on solid data, strong earnings - Yahoo Finance
OpenAI signs $38 billion deal to use Amazon's cloud platform - Yahoo Finance
'Hopeful' We'll Find Long-term Solution On China: Illumina CEO - Yahoo Finance
Jyong Biotech (NASDAQ:MENS) Stock Price Up 11.2%Here's What Happened - MarketBeat
FLOWSERVE CORPORATION (FLS) Stock, Price, News, Quotes, Forecast and Insights - MSN
Caterpillar Posts Upbeat Q3 Results, Joins United Therapeutics, Centene, Fortive And Other Big Stocks Moving Higher On Wednesday - Benzinga
Caterpillar, Nvidia Lead Market Cap Stock Movers on Wednesday By Investing.com - Investing.com Nigeria
Caterpillar, Nvidia Lead Market Cap Stock Movers on Wednesday - Investing.com India
Legend Biotech to Host Investor Conference Call on Third Quarter 2025 Results - Yahoo Finance
Jyong Biotech (NASDAQ:MENS) Stock Price Down 15.6%Here's Why - MarketBeat
Tesla and Nvidia lead market cap stock movers this Tuesday - Investing.com
Here's How Much Traders Expect Meta Stock To Move After Earnings This Week - Yahoo Finance
Tesla and Qualcomm Lead Monday’s Market Cap Stock Movers - Investing.com
Tesla and Qualcomm Lead Monday’s Market Cap Stock Movers By Investing.com - Investing.com UK
New Montreal Biotech LifeLore Pathways Launches to Accelerate Microbial Innovation - Yahoo Finance
Jyong Biotech's (MENS) "Sell (E+)" Rating Reaffirmed at Weiss Ratings - MarketBeat
BNB Jumps on CZ's Pardon - Yahoo Finance
PCI Biotech update - Yahoo Finance
Europe firms agree satellite merger to counter Starlink - Yahoo Finance
Workday Doubles Down on AI - Yahoo Finance
Jyong Biotech (NASDAQ:MENS) Stock Price Up 5.8%What's Next? - MarketBeat
Bitcoin Mining Profitability Declined More Than 7% in September: Jefferies - Yahoo Finance
FDA Grants First CNPV Vouchers, Igniting Rally in Biotech Stocks - Yahoo Finance
Kelun-Biotech Presents Positive Results of Phase 3 Clinical Study OptiTROP-Breast02 for Sacituzumab Tirumotecan in Advanced HR+/HER2- Breast Cancer at 2025 ESMO - Yahoo Finance
Salesforce forecasts $60 billion in revenue by 2030, shares jump - Yahoo Finance
Tech Weekly: Samsung defies estimates, Wayve piques interest - Yahoo Finance
Jim Cramer on Inspire Medical: “They’ve Had One Execution Issue After Another” - Yahoo Finance
LEIFRAS Co., Ltd. Announces Pricing of Initial Public Offering - Yahoo Finance
Trump Sparks A 2025 IPO Boom: 5 New Stocks Have Rallied Over 400% - Benzinga
Jyong Biotech Ltd (MENS) 재무 분석
Jyong Biotech Ltd (MENS)에 대한 금융 데이터가 없습니다. 더 많은 정보를 위해 다른 주식을 확인해보세요.
매출
순이익
현금흐름
주당 순 이익
1.38%
1.42%
자본화:
|
볼륨(24시간):